Protein trafficking abnormalities: a new mechanism in drug-induced long QT syndrome.
about
Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug developmentZebrafish: an emerging technology for in vivo pharmacological assessment to identify potential safety liabilities in early drug discovery.Iatrogenic QT Abnormalities and Fatal Arrhythmias: Mechanisms and Clinical SignificanceIn vitro chronic effects on hERG channel caused by the marine biotoxin azaspiracid-2.Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine.Molecular mechanisms for drug interactions with hERG that cause long QT syndrome.Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation.Drug-induced Inhibition and Trafficking Disruption of ion Channels: Pathogenesis of QT Abnormalities and Drug-induced Fatal Arrhythmias.Sudden cardiac death: prevalence, pathogenesis, and prevention.Strategies to reduce the risk of drug-induced QT interval prolongation: a pharmaceutical company perspective.Supplemental studies for cardiovascular risk assessment in safety pharmacology: a critical overview.Pharmacogenetics of drug-induced arrhythmias.Acquired long QT syndrome and phosphoinositide 3-kinase.Drugs and trafficking of ion channels: a new pro-arrhythmic threat on the horizon?International Life Sciences Institute (Health and Environmental Sciences Institute, HESI) initiative on moving towards better predictors of drug-induced torsades de pointes.Characterizing the effect of pentamidine isethionate on the immune system using mouse splenocytes as an experimental model.Clenbuterol Attenuates hERG Channel by Promoting the Mature Channel Degradation.
P2860
Q24646866-1067B6E8-2D8E-4226-A22C-FCC477004569Q30487697-1581BBDB-DD56-4321-9D0B-9C1CAAF455EDQ33653994-0BE19113-1F51-41D5-80E0-37AAF1F67C1BQ34615797-197E0BD4-E229-4688-80C6-40AD299C263BQ36054408-BA089854-0C62-418C-9BEA-33760D642E55Q36545039-3A415B0F-857A-459B-A53C-AFF65C1CB7F6Q36788875-D3A51844-61CF-4BE7-9414-EA4A43530154Q36886266-532295BE-7638-441F-9C1B-F7C3186F4BD9Q37165374-45F9839E-5711-4FDF-8FC6-43FC686B5C09Q37171823-DC26179F-ABB4-4C2B-B3FA-474B290F5AD5Q37909132-ABB3AA83-A35B-4501-8C3C-77DD33B8F208Q38177332-71B8F0E1-A1FC-40B2-BAC8-C6F99699EC21Q39421620-E7281ACA-DD42-4BC6-8FC8-DD7114C0350EQ41856022-A0851D56-B41B-4A01-A568-D0463B8CB1CDQ42359171-2C4C5FCF-696F-41A5-B825-9378FC160B6AQ44203247-3C727DBD-81D4-4C6A-8EA2-BF1A32491451Q50628884-DA6D985E-941D-4C10-95B0-20D18D2FB79C
P2860
Protein trafficking abnormalities: a new mechanism in drug-induced long QT syndrome.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Protein trafficking abnormalities: a new mechanism in drug-induced long QT syndrome.
@ast
Protein trafficking abnormalities: a new mechanism in drug-induced long QT syndrome.
@en
type
label
Protein trafficking abnormalities: a new mechanism in drug-induced long QT syndrome.
@ast
Protein trafficking abnormalities: a new mechanism in drug-induced long QT syndrome.
@en
prefLabel
Protein trafficking abnormalities: a new mechanism in drug-induced long QT syndrome.
@ast
Protein trafficking abnormalities: a new mechanism in drug-induced long QT syndrome.
@en
P2093
P2860
P356
P1476
Protein trafficking abnormalities: a new mechanism in drug-induced long QT syndrome.
@en
P2093
Craig T January
Lee L Eckhardt
Sridharan Rajamani
P2860
P356
10.1038/SJ.BJP.0706143
P407
P577
2005-05-01T00:00:00Z